•Utilization of adjuvant anti-PD-1 immunotherapy for stage IIB/C and stage III melanoma: Current clinical practice guidelines and consensus guidelines of the European Society of Medical Oncology (updated 2018 and 2020) endorse treatment of most patients with resected stage III melanoma,25 and immunotherapy for stage IIB/C melanoma is endorsed by the American Society for Clinical Oncology guidelines (updated 2023).26 The gene discussed is PDCD1; the disease is melanoma.